434 related articles for article (PubMed ID: 17405151)
21. Acute cardiac functional and morphological changes after Anthracycline infusions in children.
Ganame J; Claus P; Eyskens B; Uyttebroeck A; Renard M; D'hooge J; Gewillig M; Bijnens B; Sutherland GR; Mertens L
Am J Cardiol; 2007 Apr; 99(7):974-7. PubMed ID: 17398195
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
[TBL] [Abstract][Full Text] [Related]
23. Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.
Shimomura Y; Baba R; Watanabe A; Horikoshi Y; Asami K; Hyakuna N; Iwai A; Matsushita T; Yamaji K; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2011 Sep; 57(3):461-6. PubMed ID: 21298773
[TBL] [Abstract][Full Text] [Related]
24. Exercise echocardiography reflects cumulative anthracycline exposure during childhood.
Smibert E; Carlin JB; Vidmar S; Wilkinson LC; Newton M; Weintraub RG
Pediatr Blood Cancer; 2004 Jun; 42(7):556-62. PubMed ID: 15127409
[TBL] [Abstract][Full Text] [Related]
25. Late cardiotoxicity of anthracyclines in children with acute leukemia.
Zalewska-Szewczyk B; Lipiec J; Bodalski J
Klin Padiatr; 1999; 211(4):356-9. PubMed ID: 10472576
[TBL] [Abstract][Full Text] [Related]
26. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.
Abosoudah I; Greenberg ML; Ness KK; Benson L; Nathan PC
Pediatr Blood Cancer; 2011 Sep; 57(3):467-72. PubMed ID: 21280201
[TBL] [Abstract][Full Text] [Related]
27. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer].
Oberholzer K; Kunz RP; Dittrich M; Thelen M
Rofo; 2004 Sep; 176(9):1245-50. PubMed ID: 15346258
[TBL] [Abstract][Full Text] [Related]
28. [Early and late anthracycline-induced cardiotoxicity in childhood: non-invasive evaluation of contractility in 116 patients].
Agnoletti G; Bonazza A; Pennacchio M; Porta F; Arrighini A
G Ital Cardiol; 1995 Oct; 25(10):1295-305. PubMed ID: 8682225
[TBL] [Abstract][Full Text] [Related]
29. A longitudinal study of cardiac function in children with cancer over 40 months.
Li CK; Sung RY; Kwok KL; Leung TF; Shing MM; Chik KW; Yu CW; Yam MC; Yuen PM
Pediatr Hematol Oncol; 2000; 17(1):77-83. PubMed ID: 10689717
[TBL] [Abstract][Full Text] [Related]
30. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cardiotoxicity by tissue Doppler imaging in childhood leukemia survivors treated with low-dose anthracycline.
Bayram C; Çetin İ; Tavil B; Yarali N; Ekici F; Isık P; Tunc B
Pediatr Cardiol; 2015 Apr; 36(4):862-6. PubMed ID: 25577226
[TBL] [Abstract][Full Text] [Related]
32. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
Elbl L; Vasova I; Tomaskova I; Jedlicka F; Navratil M; Pospisil Z; Vorlicek J
Neoplasma; 2006; 53(2):174-81. PubMed ID: 16575475
[TBL] [Abstract][Full Text] [Related]
33. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
34. Tissue Doppler and myocardial deformation imaging to detect myocardial dysfunction in pediatric cancer patients treated with high doses of anthracyclines.
Yağci-Küpeli B; Varan A; Yorgun H; Kaya B; Büyükpamukçu M
Asia Pac J Clin Oncol; 2012 Dec; 8(4):368-74. PubMed ID: 22898185
[TBL] [Abstract][Full Text] [Related]
35. Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines.
Pourier MS; Mavinkurve-Groothuis AMC; Dull MM; Weijers G; Loonen J; Bellersen L; de Korte CL; Kapusta L
Am J Cardiol; 2020 Jul; 127():163-168. PubMed ID: 32444028
[TBL] [Abstract][Full Text] [Related]
36. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
[TBL] [Abstract][Full Text] [Related]
37. Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors.
De Caro E; Smeraldi A; Trocchio G; Calevo M; Hanau G; Pongiglione G
Pediatr Blood Cancer; 2011 Jan; 56(1):122-6. PubMed ID: 21058389
[TBL] [Abstract][Full Text] [Related]
38. Growth-differentiation factor-15 and tissue doppler ımaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors.
Arslan D; Cihan T; Kose D; Vatansev H; Cimen D; Koksal Y; Oran B; Akyurek F
Clin Biochem; 2013 Sep; 46(13-14):1239-43. PubMed ID: 23850849
[TBL] [Abstract][Full Text] [Related]
39. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
[TBL] [Abstract][Full Text] [Related]
40. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.
Zerra P; Cochran TR; Franco VI; Lipshultz SE
Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
